(ASND) Ascendis Pharma AS - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 14.317m USD | Total Return: 66.9% in 12m

Endocrinology, Therapies, Rare Diseases, Oncology
Total Rating 48
Safety 33
Buy Signal -0.31
Biotechnology
Industry Rotation: -3.7
Market Cap: 14.3B
Avg Turnover: 102M USD
ATR: 3.96%
Peers RS (IBD): 44.8
Risk 5d forecast
Volatility41.3%
Rel. Tail Risk-17.4%
Reward TTM
Sharpe Ratio1.58
Alpha53.87
Character TTM
Beta0.469
Beta Downside0.477
Drawdowns 3y
Max DD29.15%
CAGR/Max DD1.50
EPS (Earnings per Share) EPS (Earnings per Share) of ASND over the last years for every Quarter: "2021-03": -1.17, "2021-06": -2.5, "2021-09": -1.47, "2021-12": -1.87, "2022-03": -2.21, "2022-06": -1.46, "2022-09": -3.03, "2022-12": -3.7, "2023-03": -1.98, "2023-06": -2.16, "2023-09": -2.88, "2023-12": -1.54, "2024-03": -2.3, "2024-06": -2.11, "2024-09": -1.72, "2024-12": -0.64, "2025-03": -1.58, "2025-06": -0.64, "2025-09": -1, "2025-12": -0.55, "2026-03": 0,
EPS CAGR: 13.49%
EPS Trend: 79.4%
Last SUE: -0.75
Qual. Beats: 0
Revenue Revenue of ASND over the last years for every Quarter: 2021-03: 0.746, 2021-06: 1.022, 2021-09: 1.113, 2021-12: 4.897, 2022-03: 6.828, 2022-06: 6.16, 2022-09: 15.29, 2022-12: 22.896, 2023-03: 33.589, 2023-06: 47.393, 2023-09: 48.034, 2023-12: 137.702, 2024-03: 95.894, 2024-06: 35.998, 2024-09: 57.833, 2024-12: 173.916, 2025-03: 100.954, 2025-06: 158.045, 2025-09: 213.634, 2025-12: 245.179077, 2026-03: null,
Rev. CAGR: 159.85%
Rev. Trend: 87.9%
Last SUE: -0.28
Qual. Beats: 0

Warnings

Negative Equity with losses - insolvent profile

Interest Coverage Ratio -0.6 is critical

Altman Z'' -9.02 < 1.0 - financial distress zone

Volatile

Tailwinds

No distinct edge detected

Description: ASND Ascendis Pharma AS

Ascendis Pharma A/S (ASND) is a biopharmaceutical company that develops therapies for unmet medical needs. The companys core technology is TransCon. Biopharmaceutical companies develop drugs derived from living organisms.

ASND markets SKYTROFA for pediatric growth hormone deficiency and YORVIPATH for chronic hypoparathyroidism in adults. Both are TransCon-based therapies. The company also has a pipeline of three endocrinology rare disease candidates in clinical development and is advancing oncology therapeutic candidates. A key aspect of the biopharmaceutical business model is the lengthy and costly drug development and approval process.

For more detailed financial analysis, consider exploring ValueRay.

Headlines to Watch Out For
  • SKYTROFA sales growth drives revenue expansion
  • YORVIPATH commercialization success impacts profitability
  • Clinical trial results for pipeline candidates influence valuation
  • Regulatory approvals for new drugs create significant upside
Piotroski VR‑10 (Strict) 5.0
Net Income: -227.7m TTM > 0 and > 6% of Revenue
FCF/TA: 0.03 > 0.02 and ΔFCF/TA 29.36 > 1.0
NWC/Revenue: 5.51% < 20% (prev 42.07%; Δ -36.56% < -1%)
CFO/TA 0.04 > 3% & CFO 51.2m > Net Income -227.7m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.04 > 1.5 & < 3
Outstanding Shares: last quarter (61.4m) vs 12m ago 2.67% < -2%
Gross Margin: 86.28% > 18% (prev 0.88%; Δ 8.54k% > 0.5%)
Asset Turnover: 57.85% > 50% (prev 30.83%; Δ 27.02% > 0%)
Interest Coverage Ratio: -0.62 > 6 (EBITDA TTM -80.7m / Interest Expense TTM 158.9m)
Altman Z'' -9.02
A: 0.03 (Total Current Assets 1.11b - Total Current Liabilities 1.07b) / Total Assets 1.30b
B: -2.07 (Retained Earnings -2.70b / Total Assets 1.30b)
C: -0.08 (EBIT TTM -98.3m / Avg Total Assets 1.24b)
D: -1.84 (Book Value of Equity -2.69b / Total Liabilities 1.46b)
Altman-Z'' Score: -9.02 = D
Beneish M -2.28
DSRI: 0.48 (Receivables 157.6m/166.3m, Revenue 717.8m/363.6m)
GMI: 1.02 (GM 86.28% / 87.83%)
AQI: 2.14 (AQ_t 0.04 / AQ_t-1 0.02)
SGI: 1.97 (Revenue 717.8m / 363.6m)
TATA: -0.21 (NI -227.7m - CFO 51.2m) / TA 1.30b)
Beneish M-Score: -2.28 (Cap -4..+1) = BBB
What is the price of ASND shares? As of April 11, 2026, the stock is trading at USD 239.28 with a total of 677,985 shares traded.
Over the past week, the price has changed by +5.55%, over one month by -0.52%, over three months by +14.62% and over the past year by +66.94%.
Is ASND a buy, sell or hold? Ascendis Pharma AS has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy ASND.
  • StrongBuy: 12
  • Buy: 4
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the ASND price?
Analysts Target Price 293.2 22.5%
Ascendis Pharma AS (ASND) - Fundamental Data Overview as of 10 April 2026
Market Cap EUR = 12.25b (14.32b USD * 0.8553 USD.EUR)
P/E Forward = 42.735
P/S = 19.8809
P/B = 78.1335
Revenue TTM = 717.8m EUR
EBIT TTM = -98.3m EUR
EBITDA TTM = -80.7m EUR
Long Term Debt = 385.3m EUR (from longTermDebt, last quarter)
Short Term Debt = 486.3m EUR (from shortTermDebt, last quarter)
Debt = 871.4m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 255.6m EUR (from netDebt column, last quarter)
Enterprise Value = 12.50b EUR (12.25b + Debt 871.4m - CCE 615.8m)
Interest Coverage Ratio = -0.62 (Ebit TTM -98.3m / Interest Expense TTM 158.9m)
EV/FCF = 292.2x (Enterprise Value 12.50b / FCF TTM 42.8m)
FCF Yield = 0.34% (FCF TTM 42.8m / Enterprise Value 12.50b)
FCF Margin = 5.96% (FCF TTM 42.8m / Revenue TTM 717.8m)
Net Margin = -31.72% (Net Income TTM -227.7m / Revenue TTM 717.8m)
Gross Margin = 86.28% ((Revenue TTM 717.8m - Cost of Revenue TTM 98.5m) / Revenue TTM)
Gross Margin QoQ = 88.91% (prev 89.54%)
Tobins Q-Ratio = 9.60 (Enterprise Value 12.50b / Total Assets 1.30b)
Interest Expense / Debt = 7.05% (Interest Expense 61.4m / Debt 871.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -77.7m (EBIT -98.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.04 (Total Current Assets 1.11b / Total Current Liabilities 1.07b)
 Debt / Equity = -5.35 (negative equity) (Debt 871.4m / totalStockholderEquity, last quarter -162.8m)
 Debt / EBITDA = -3.17 (negative EBITDA) (Net Debt 255.6m / EBITDA -80.7m)
 Debt / FCF = 5.98 (Net Debt 255.6m / FCF TTM 42.8m)
Total Stockholder Equity = -178.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -18.35% (Net Income -227.7m / Total Assets 1.30b)
 RoE = 127.5% (negative equity) (Net Income TTM -227.7m / Total Stockholder Equity -178.6m)
 RoCE = -47.57% (EBIT -98.3m / Capital Employed (Equity -178.6m + L.T.Debt 385.3m))
 RoIC = -11.90% (negative operating profit) (NOPAT -77.7m / Invested Capital 652.7m)
 WACC = 7.49% (E(12.25b)/V(13.12b) * Re(7.63%) + D(871.4m)/V(13.12b) * Rd(7.05%) * (1-Tc(0.21)))
Discount Rate = 7.63% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 100.0 | Cagr: 4.12%
[DCF] Terminal Value 73.93% ; FCFF base≈42.8m ; Y1≈29.2m ; Y5≈14.5m
[DCF] Fair Price = 0.93 (EV 312.5m - Net Debt 255.6m = Equity 56.9m / Shares 61.4m; r=7.49% [WACC]; 5y FCF grow -37.08% → 3.0% )
EPS Correlation: 79.40 | EPS CAGR: 13.49% | SUE: -0.75 | # QB: 0
Revenue Correlation: 87.91 | Revenue CAGR: 159.8% | SUE: -0.28 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.91 | Chg7d=-0.049 | Chg30d=-0.049 | Revisions Net=-1 | Analysts=10
EPS current Year (2026-12-31): EPS=4.37 | Chg7d=-0.191 | Chg30d=-0.151 | Revisions Net=-4 | Growth EPS=+216.1% | Growth Revenue=+92.2%
EPS next Year (2027-12-31): EPS=10.69 | Chg7d=-0.442 | Chg30d=-0.343 | Revisions Net=-2 | Growth EPS=+144.9% | Growth Revenue=+40.9%
[Analyst] Revisions Ratio: -0.33 (1 Up / 2 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle